Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New issues in tuberculosis.

S H E Kaufmann1

  • 1Max Planck Institute for Infection Biology, Department of Immunology, Schumannstr, 21-22, 10117 Berlin, Germany. kaufmann@mpiib-berlin.mpg.de

Annals of the Rheumatic Diseases
|October 14, 2004
PubMed
Summary

A new recombinant Bacillus Calmette-Guérin (BCG) vaccine offers enhanced protection against tuberculosis (TB). This novel vaccine shows superior efficacy compared to the traditional BCG vaccine against Mycobacterium tuberculosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.

The Lancet. Infectious diseases·2022
Same author

History of BCG Vaccination Recommendations in East and West Germany from 1951 to Date.

Pneumologie (Stuttgart, Germany)·2020
Same author

[DZK Recommendations for Tuberculosis, BCG and COVID-19 in Germany - (Official Abbreviation of Coronavirus Disease 2019 Caused by the New Coronavirus SARS-CoV-2)].

Pneumologie (Stuttgart, Germany)·2020
Same author

Differential transcriptomic and metabolic profiles of M. africanum- and M. tuberculosis-infected patients after, but not before, drug treatment.

Genes and immunity·2015
Same author

Molecular signatures for vaccine development.

Vaccine·2015
Same author

Differential gene expression of activating Fcγ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2013

Area of Science:

  • Immunology
  • Microbiology
  • Vaccinology

Background:

  • Tuberculosis (TB) is a significant global health challenge caused by Mycobacterium tuberculosis.
  • The current M. bovis BCG vaccine provides limited protection against adult pulmonary TB.
  • Understanding T cell responses is crucial for developing effective TB vaccines.

Purpose of the Study:

  • To develop a novel recombinant BCG vaccine for improved tuberculosis prevention.
  • To evaluate the efficacy of the recombinant BCG vaccine against Mycobacterium tuberculosis.

Main Methods:

  • Construction of a recombinant BCG vaccine.
  • Comparative protection assays against laboratory strains and clinical isolates of M. tuberculosis.

Main Results:

  • The recombinant BCG vaccine induced superior protection compared to wild-type BCG.
  • This enhanced protection was observed against both laboratory strains and clinical isolates of M. tuberculosis.

Conclusions:

  • The developed recombinant BCG vaccine represents a promising candidate for a novel tuberculosis vaccine.
  • Further research into T cell-mediated immunity can guide the design of next-generation TB vaccines.

Related Experiment Videos